Ignite Creation Date:
2024-05-06 @ 7:26 AM
Last Modification Date:
2024-10-26 @ 11:48 AM
Study NCT ID:
NCT02536625
Status:
COMPLETED
Last Update Posted:
2021-02-04
First Post:
2015-08-14
Brief Title:
Study of the Impact of Everolimus Treatment on Lymphocytes NK Natural Killer Development and Functions for Patients With a Metastatic Breast Cancer HR HER2Neu Negative
Sponsor:
Centre Leon Berard
Organization:
Centre Leon Berard
Study Overview
Official Title:
RAPANK Study of the Impact of Everolimus Treatment on the Development and Functions of Lymphocytes NK Natural Killer for Patients With a Metastatic Breast Cancer HR HER2Neu Negative
Status:
COMPLETED
Status Verified Date:
2021-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RAPANK
Brief Summary:
NK Natural Killer cells are important in the fight against tumor especially for the control of cancer metastasis The purpose of this prospective study is to evaluate the impact on lymphocytes NK functions and development of an everolimus treatment in women treated for a metastatic breast cancer In particular the study of lymphocytes NK functions and development under everolimus treatment could permit to validate an early biomarker of the impact of everolimus on these NK cells
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None